9.9608 0.221 (2.27%) | 02-14 15:59 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 10.34 | 1-year : | 13.56 |
Resists | First : | 8.85 | Second : | 11.6 |
Pivot price | 7.16 | |||
Supports | First : | 4.4 | Second : | 3.66 |
MAs | MA(5) : | 6.9 | MA(20) : | 7.06 |
MA(100) : | 9.27 | MA(250) : | 9.8 | |
MACD | MACD : | -0.3 | Signal : | -0.4 |
%K %D | K(14,3) : | 16 | D(3) : | 23.3 |
RSI | RSI(14): 45.7 | |||
52-week | High : | 26.59 | Low : | 3.05 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ AEHA ] has closed above bottom band by 18.2%. Bollinger Bands are 40% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 7.2 - 7.23 | 7.23 - 7.26 |
Low: | 6.55 - 6.59 | 6.59 - 6.63 |
Close: | 6.58 - 6.65 | 6.65 - 6.7 |
Aesther Healthcare Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses primarily in the pharmaceutical and medical devices sectors. The company was incorporated in 2021 and is based in New York, New York.
Wed, 15 Feb 2023
Aesther Healthcare Acquisition Corp. (AEHA) Closes Ocean Biomedical Deal|SPACInsider - SPACInsider
Wed, 01 Feb 2023
Ocean Biomedical SPAC deal set for shareholder vote - Providence Business First - The Business Journals
Tue, 24 Jan 2023
Ocean Biomedical Provides Corporate Update and Company Summary - GlobeNewswire
Tue, 13 Dec 2022
Aesther Healthcare Acquisition Corp. Announces Intention to Extend Period to Consummate Business Combination - GlobeNewswire
Thu, 08 Sep 2022
Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) and Ocean Biomedical, Inc. Announce $75 Million Common ... - GlobeNewswire
Tue, 06 Sep 2022
Discovery of Bispecific Antibodies and Immune Checkpoint Inhibitors That Kill Glioblastoma Cells and Melanoma Cells ... - Yahoo Finance
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Financial Services
|
|
Industry:
Shell Companies
|
|
Shares Out | 11 (M) |
Shares Float | 10 (M) |
Held by Insiders | 9.6 (%) |
Held by Institutions | 105.2 (%) |
Shares Short | 3 (K) |
Shares Short P.Month | 3 (K) |
EPS | 0 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | -0.35 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | 0 % |
Return on Equity (ttm) | 0 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | 0 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -2 (M) |
Levered Free Cash Flow | 0 (M) |
PE Ratio | 0 |
PEG Ratio | 0 |
Price to Book value | -18.98 |
Price to Sales | 0 |
Price to Cash Flow | -44.27 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |